Miller Investment Management LP grew its position in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 13.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 207,535 shares of the company’s stock after buying an additional 24,446 shares during the period. VanEck Pharmaceutical ETF accounts for approximately 2.1% of Miller Investment Management LP’s investment portfolio, making the stock its 10th largest position. Miller Investment Management LP owned 2.81% of VanEck Pharmaceutical ETF worth $19,722,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Beck Capital Management LLC raised its holdings in VanEck Pharmaceutical ETF by 5.2% in the 3rd quarter. Beck Capital Management LLC now owns 22,383 shares of the company’s stock valued at $2,127,000 after buying an additional 1,109 shares during the period. Townsquare Capital LLC boosted its position in shares of VanEck Pharmaceutical ETF by 3.8% during the 3rd quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock worth $334,000 after purchasing an additional 130 shares during the period. FMR LLC increased its holdings in VanEck Pharmaceutical ETF by 12.5% in the 3rd quarter. FMR LLC now owns 1,905 shares of the company’s stock valued at $181,000 after purchasing an additional 212 shares during the last quarter. Bank of Montreal Can raised its position in VanEck Pharmaceutical ETF by 43.6% in the third quarter. Bank of Montreal Can now owns 21,640 shares of the company’s stock valued at $2,052,000 after purchasing an additional 6,570 shares during the period. Finally, Thrivent Financial for Lutherans boosted its position in shares of VanEck Pharmaceutical ETF by 33.6% during the third quarter. Thrivent Financial for Lutherans now owns 234,890 shares of the company’s stock worth $22,322,000 after buying an additional 59,025 shares during the period.
VanEck Pharmaceutical ETF Trading Up 0.3 %
Shares of NASDAQ PPH opened at $90.48 on Wednesday. The stock has a fifty day simple moving average of $91.72 and a 200-day simple moving average of $93.04. VanEck Pharmaceutical ETF has a twelve month low of $77.70 and a twelve month high of $99.51. The stock has a market capitalization of $668.65 million, a PE ratio of 21.04 and a beta of 0.72.
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Read More
- Five stocks we like better than VanEck Pharmaceutical ETF
- What is Short Interest? How to Use It
- 3 Small-Cap Stocks on the Rise With Over 4% Dividend Yields
- What Are the U.K. Market Holidays? How to Invest and Trade
- Insiders Keep Buying These Stocks: 2 to Buy, 1 to Avoid
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Triumph Financial Stock Breakout: Why It’s Just the Beginning
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.